Gastroenterology Market Report and Forecast 2025-2034

U.S. Gastroenterology Market Size and Growth 2024 to 2034

The United States gastroenterology market growth is driven by the increasing prevalence of gastrointestinal disorders, an aging population, and rising healthcare expenditures in the region. Key trends include the adoption of biologics and biosimilars for treating conditions like inflammatory bowel disease and Crohn's disease, as well as the integration of genetic data and biomarkers in personalized medicine to tailor treatments to individual patients.

Market Overview

Gastroenterology is a medical specialty focused on diagnosing and treating disorders of the digestive system, including the stomach, intestines, liver, pancreas, and gallbladder. Common conditions such as gastroesophageal reflux disease (GERD), inflammatory bowel disease (IBD), and colorectal cancer. Advancements in diagnostics, therapeutics, and minimally invasive procedures have significantly improved patient outcomes, driving continuous innovation in the field.

The key drivers of market growth include the increasing prevalence of digestive disorders, a rising ageing population, and the growing demand for minimally invasive procedures. Additionally, advancements in biologics, precision medicine, and AI-driven diagnostics are improving early disease detection and treatment effectiveness. The shift towards outpatient care and home-based treatments also supports market expansion.

The market is expected to grow further due to factors such as unhealthy dietary habits, sedentary lifestyles, the rise in gastrointestinal surgeries, and continuous innovation in gastroenterology therapeutics and medical devices.

Gastroenterology Market Growth Factors

The gastroenterology market is experiencing significant growth due to the increasing prevalence of digestive disorders linked to modern dietary habits, stress, and environmental factors. Rising obesity rates and high consumption of processed foods contribute to gastrointestinal conditions such as non-alcoholic fatty liver disease (NAFLD) and acid reflux. Additionally, the increasing use of antibiotics and medications that disrupt gut microbiota has led to higher cases of dysbiosis, prompting greater demand for probiotics and gut-health-focused treatments. The integration of telemedicine and digital health solutions has also expanded access to gastroenterology care, enabling early diagnosis and personalised treatment plans.

Another key driver is the surge in gut-brain axis research, which highlights the impact of gastrointestinal health on neurological and psychological conditions, driving interest in novel treatment approaches. The expansion of robotic-assisted endoscopic procedures enhances precision in gastrointestinal surgeries, reducing complications and recovery times. Government initiatives promoting digestive health awareness and preventive screening programmes further boost market demand, ensuring continued advancements in gastroenterology diagnostics and therapeutics.

Market Dynamics

Market Drivers

The gastroenterology market is expanding due to continuous product launches and technological advancements. The development of next-generation biologics, biosimilars, and targeted therapies is transforming treatment options for chronic conditions like Crohn’s disease and ulcerative colitis. Innovations such as AI-powered diagnostic tools, capsule endoscopy, and robotic-assisted procedures are improving diagnostic accuracy and treatment precision, enhancing patient outcomes.

Strategic investments and collaborations among pharmaceutical companies, research institutions, and healthcare providers are driving innovation. Increased funding for gastrointestinal research and clinical trials is accelerating drug development. Partnerships between biotech firms and medical device manufacturers are fostering the introduction of novel therapeutic solutions. Government initiatives promoting digestive health awareness and early screening programmes further contribute to market expansion.

Market Restraints

Despite growth, the gastroenterology market faces challenges such as the high cost of advanced therapies and medical devices. Many biologics and targeted treatments remain expensive, limiting access for patients in low- and middle-income countries. Additionally, the reimbursement landscape for gastroenterology procedures varies, creating financial barriers for patients seeking specialised care.

Regulatory complexities and prolonged approval timelines for new drugs and medical technologies hinder market growth. Strict safety requirements and extensive clinical trial processes delay product launches, slowing innovation. Furthermore, the rising prevalence of antibiotic resistance and the limited effectiveness of conventional treatments for certain gastrointestinal disorders pose significant challenges, requiring ongoing research and development efforts.

Market Opportunities

The increasing adoption of personalised medicine and microbiome-based therapies presents a major market opportunity. Advances in genetic profiling and gut microbiome research allow for tailored treatment approaches, improving efficacy and patient satisfaction. Additionally, the rising demand for minimally invasive procedures and telemedicine solutions is expanding access to gastroenterology care, driving further market growth.

Gastroenterology Market Trends

The gastroenterology market is experiencing rapid advancements, particularly with the rising prevalence of inflammatory bowel disease (IBD) in the United States, estimated between 2.4 and 3.1 million cases. With annual healthcare costs reaching USD 8.5 billion in 2018, the demand for innovative treatments continues to grow. Targeted biologic therapies, including monoclonal antibodies and immune-modulating treatments, are transforming disease management by offering personalised and precision-based care. Increasing pharmaceutical investments in specialised drugs and minimally invasive treatments will further drive market expansion, addressing previously unmet medical needs and improving patient outcomes in the coming years.

The integration of artificial intelligence (AI) in gastroenterology is reshaping the industry. The Gastro AI Academy in India, launched in August 2024 , reflected the increasing demand for AI-based training and innovation. By educating GI physicians and surgeons on AI applications, this initiative aimed to enhance diagnostic accuracy and treatment efficiency. With FUJIFILM India as an academic partner, the program underscored the role of industry collaborations in advancing AI-driven healthcare solutions.

AI-driven diagnostic tools are also becoming a game changer in endoscopy. For instance, in October  2024, GI Alliance partnered with Medtronic to implement GI Genius, an AI-powered endoscopy module that enhances polyp detection during colonoscopies. The technology significantly reduces missed polyps, improving early colorectal cancer detection. With deployment across 400 sites, AI-assisted endoscopy is set to become a standard in gastrointestinal diagnostics, driving market expansion.

The gastroenterology market is rapidly evolving, with biologic drug development, AI education, and AI-powered diagnostics shaping the industry's future. As technological advancements and strategic collaborations continue, the market is expected to witness faster disease detection, improved treatment outcomes, and greater accessibility to innovative therapies.

Treatment Type Insights

The gastroenterology market is segmented into devices, and therapeutics, each driving market expansion. Proton pump inhibitors and H2 antihistamines remain crucial for acid-related disorders, while endoscopy and therapeutic devices enhance diagnosis and treatment precision. Growing demand for minimally invasive procedures, technological advancements, and innovative diagnostics will propel this segment’s growth in the forecast period.

Distribution Channel Insights

Based on distribution channels, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. Hospitals pharmacies and retail pharmacies will likely dominate the gastroenterology market due to advanced healthcare infrastructure and increasing endoscopic procedures. The rise of online pharmacies and retail outlets has improved accessibility, while specialty clinics and research institutes drive innovation. Expanding telehealth services and direct-to-consumer distribution are expected to transform market dynamics in the forecast period.

Application Insights

Gastroenterology applications include Crohn’s disease, ulcerative colitis, gastroesophageal reflux disease (GERD), irritable bowel syndrome (IBS) and others. The increasing prevalence of digestive disorders, sedentary lifestyles, and unhealthy diets fuel demand for advanced treatments. The segment benefits from new drug developments, targeted therapies, and minimally invasive surgical interventions, contributing to improved patient outcomes and sustained market growth.

Route of Administration

The gastroenterology market by route of administration encompasses oral, injectable, and others. Among these, oral administration is the most preferred due to ease of use and patient compliance. Injectable treatments are gaining traction for severe conditions, while other formulations cater to localised treatment needs. Innovations in drug delivery systems and biologics are expected to enhance therapeutic efficacy.

Gastroenterology Market Companies

• Abbott
• Johnson & Johnson Services Inc.
• AbbVie Inc.
• Salix Pharmaceuticals
• GlaxoSmithKline Plc
• Takeda Pharmaceutical Company Limited
• Astellas Pharma US, Inc.
• Pfizer Inc.
• AstraZeneca plc

Recent Development

• In January 2025, ArriVent BioPharma, Inc., a clinical-stage company focused on advancing innovative biopharmaceutical therapies globally, announced about signing of an exclusive license agreement with Lepu Biopharma Co., Ltd for MRG007, an antibody-drug conjugate (ADC) intended to treat various gastrointestinal (GI) cancers. As part of the agreement, ArriVent secured the exclusive rights to develop and market MRG007 worldwide, excluding Greater China, which covered mainland China, Hong Kong, Macau, and Taiwan.
• In March 2025, Sunshine Biopharma Inc., a pharmaceutical company focused on oncology and antivirals, announced that its Canadian subsidiary, Nora Pharma Inc., acquired the rights to two gastrointestinal drugs, launching one and planning the second within nine months. The newly introduced drug, Prucalopride, a generic of Resotran® (Motegrity® in the US), treats chronic idiopathic constipation in adult women unresponsive to laxatives. It stimulates 5-HT4 receptors, enhancing intestinal motility by promoting neurotransmission, peristalsis, and secretions in the gastrointestinal tract.
• In January 2024, the FDA approved dupilumab (Dupixent) for pediatric eosinophilic esophagitis (EoE) patients aged 1-11 years weighing ≥ 15 kg, making it the first and only FDA-approved treatment for this population. This expands its May 2022 approval for patients ≥ 12 years weighing ≥ 40 kg, further strengthening its role in EoE treatment.
• In November 2024, Washington Gastroenterology (WaGI) partnered with WovenX Health to enhance GI care delivery via on-demand telehealth. Findings presented at the American College of Gastroenterology Conference showed a 97% virtual care appropriateness rate, reduced emergency department (ED) visits, and a Net Promoter Score of 94/100, reflecting high patient satisfaction and improved accessibility in gastrointestinal healthcare.
• In October 2024, Clario and PathAI announced a strategic partnership to improve diagnostic accuracy in gastrointestinal clinical trials. Their co-delivery model streamlines endoscopic and histopathology endpoints, benefiting CROs, sponsors, and research sites with enhanced workflows, training, and digital pathology analysis, optimising efficiency in global GI studies and accelerating clinical research advancements.
• In July 2024, the FDA approved vonoprazan for nonerosive GERD-related heartburn in adults. Previously, vonoprazan was approved for erosive esophagitis treatment, maintenance, and Helicobacter pylori eradication in combination with antibiotics. This latest approval expands its therapeutic applications, reinforcing its role in acid-related disorders and providing a novel treatment option for GERD patients.
• In June 2024, Sun Pharmaceutical Industries Ltd. partnered with Takeda Pharmaceutical Company Ltd. to introduce an innovative GI drug in India. The MoU marks a major step in expanding access to advanced gastrointestinal treatments, strengthening India’s gastroenterology market, and enhancing treatment options for various digestive disorders.
• In October 2024, Phathom Pharmaceuticals, Inc. presented VOQUEZNA® (vonoprazan) data at the ACG 2024 Annual Scientific Meeting. VOQUEZNA®, a first-in-class FDA-approved PCAB, treats non-erosive GERD, erosive GERD, and Helicobacter pylori infections. Its novel acid-suppression mechanism positions it as a pioneering treatment for gastrointestinal acid-related disorders, driving advancements in digestive healthcare.
• In October 2024, Astellas Pharma’s zolbetuximab (Vyloy) received FDA approval for advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma. Based on two Phase 3 trials, Vyloy, in combination with chemotherapy regimens (FOLFOX6, CAPOX), represents the first therapy in a new oncology class, offering targeted treatment options for HER2-negative gastric and GEJ cancer patients.
• In April 2024, Medtronic launched ColonPRO™, the latest software for its GI Genius intelligent endoscopy system, enhancing AI-driven colonoscopy. The company also partnered with Modernizing Medicine® (ModMed) to integrate Gastro EHR, improving documentation and workflow efficiency. These advancements highlight Medtronic’s commitment to synergistic AI-powered gastroenterology solutions.

Segments Covered in the Report